CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX: XJO) is tipped to open slightly lower on Friday with the most popular Sydney Futures Exchange contract pointing to a 14-point decline from yesterday. Here’s what you need to know.
Is the CSL (ASX:CSL) share price a buy after the healthcare giant announced new debt to strengthen its debt maturity profile.
If you’re looking for the top ASX dividend income shares you’re probably looking at the dividend yield of Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) shares.
Is CSL (ASX:CSL) the best COVID-19 recovery stock to buy for your portfolio?
The latest of my “Never Sell stocks” is one of Australia’s true global leaders, CSL Limited (ASX: CSL).
The S&P/ASX 200 (ASX:XJO) has gone nuts in recent days. It’s up another 3.3% right now.
Is the CSL (ASX: CSL) share price worth just $200? It’s what some analysts seem to think.
The S&P/ASX 200 (ASX: XJO) finished the day trading at 5539.3, or 4.42% higher, having fallen more than 6% down this morning. That makes today a 10% snap-back for the ASX 200!
Cochlear Limited (ASX:COH) shares were down 4% today following their Annual General Meeting (AGM). Is it time to buy Cochlear shares?
